oral glp-1 agonists FDA just approved orforglipron (Foundayo), Eli Lilly's receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest 🕰️60-second review: Mnemonics and

oral glp-1 agonists FDA just approved orforglipron (Foundayo), Eli Lilly's receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest 🕰️60-second review: Mnemonics and

🕰️60-second review: Mnemonics and Updates in GLP-1 agonists in Obesity⁠ ⁠ GLP-1 agonists are EVERYWHERE in clinical practice right now—and they're HIGH-YIELD for NAPLEX! 💉⁠ ⁠ Know your Wegovy from your Saxenda?

Generic medications tend to be “Sandoz is building its GLP-1 development platform, and this submission reflects true in-house innovation,” said Claire D’Abreu-Hayling, the president of Generics Development and the chief scientific officer at Sandoz, in a press statement

doi: 10.1016/j.rbmo.2014.02.011 98 ZhouLQuHYangLShouL